Fulgent Stock Analysis

FLGT -  USA Stock  

USD 61.50  5.31  7.95%

The newest drop in stock price could raise concerns from private investors as the firm it trading at a share price of 61.50 on 575,856 in volume. The company directors and management have failed to build on market volatilities in December. However, diversifying your overall positions with Fulgent Genetics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.38. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Fulgent Genetics partners.
Please check Investing Opportunities.

Fulgent Stock Analysis 

 
Refresh
The Fulgent Genetics stock analysis report makes it easy to digest most publicly released information about Fulgent Genetics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Fulgent Stock analysis module also helps to analyze the Fulgent Genetics price relationship with some important fundamental indicators such as market cap and management efficiency.

Fulgent Stock Analysis Notes

About 33.0% of the company shares are held by company insiders. The book value of Fulgent Genetics was currently reported as 34.76. The company recorded earning per share (EPS) of 19.06. Fulgent Genetics had not issued any dividends in recent years. Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. Fulgent Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 480 people. To learn more about Fulgent Genetics call Ming Hsieh at 626 350 0537 or check out https://www.fulgentgenetics.com.

Fulgent Genetics Quarterly Cost of Revenue

43.47 MillionShare

Fulgent Genetics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fulgent Genetics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fulgent Genetics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Fulgent Genetics generated a negative expected return over the last 90 days
Fulgent Genetics has high historical volatility and very poor performance
Fulgent Genetics has high likelihood to experience some financial distress in the next 2 years
About 33.0% of the company shares are held by company insiders
Latest headline from www.evaluate.com: Diabetes device makers lead the smaller medtechs - Vantage

Fulgent Genetics Upcoming and Recent Events

Earnings reports are used by Fulgent Genetics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fulgent Genetics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of March 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End3rd of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Fulgent Largest EPS Surprises

Earnings surprises can significantly impact Fulgent Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-08-07
2017-06-300.0160.020.00425 
2019-02-28
2018-12-31-0.015-0.010.00533 
2018-11-06
2018-09-30-0.025-0.033-0.00832 
View All Earnings Estimates

Fulgent Genetics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Fulgent Genetics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Fulgent Genetics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Fulgent Genetics specific information freely available to individual and institutional investors to make a timely investment decision.
9th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
9th of August 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
12th of July 2021
Unclassified Corporate Event
View
20th of May 2021
Submission of Matters to a Vote of Security Holders
View
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Fulgent Genetics Thematic Classifications

In addition to having Fulgent Genetics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Healthcare IdeaHealthcare
USA Equities from Healthcare industry as classified by Fama & French
Healthcare IdeaHealthcare
USA Equities from Healthcare industry as classified by Fama & French

Fulgent Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Fulgent Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulgent Genetics backward and forwards among themselves. Fulgent Genetics' institutional investor refers to the entity that pools money to purchase Fulgent Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Nepsis IncCommon Shares93.9 K9.4 M
Exchange Traded Concepts LlcCommon Shares32.2 K3.2 M
State Of Alaska Department Of RevenueCommon Shares13.7 K1.4 M
Stonnington Group LlcCommon Shares12.2 KM
Louisiana State Employees Retirement SystemCommon Shares9.4 K946 K
Valeo Financial Advisors LlcCommon Shares8.6 K863 K
Wedbush Securities Inc 1Common Shares3.9 K394 K
Susquehanna International Group LlpPut Options304.5 K27.4 M
Note, although Fulgent Genetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Fulgent Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.39 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fulgent Genetics's market, we take the total number of its shares issued and multiply it by Fulgent Genetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Fulgent Profitablity

Fulgent Genetics' profitability indicators refer to fundamental financial ratios that showcase Fulgent Genetics' ability to generate income relative to its revenue or operating costs. If, let's say, Fulgent Genetics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Fulgent Genetics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Fulgent Genetics' profitability requires more research than a typical breakdown of Fulgent Genetics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 54.96 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 73.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.73.
Last ReportedProjected for 2022
Return on Average Assets 0.87  0.94 
Return on Average Equity 1.07  1.15 
Return on Invested Capital 1.64  1.77 
Return on Sales 0.78  0.84 

Management Efficiency

The entity has return on total asset (ROA) of 65.35 % which means that it generated profit of $65.35 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 92.39 %, meaning that it created $92.39 on every $100 dollars invested by stockholders. Fulgent Genetics management efficiency ratios could be used to measure how well fulgent genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to gain to 0.94 in 2022. Return on Average Equity is likely to gain to 1.15 in 2022. Fulgent Genetics Total Liabilities is comparatively stable at the moment as compared to the past year. Fulgent Genetics reported Total Liabilities of 150.74 Million in 2021. Current Liabilities is likely to gain to about 161.4 M in 2022, whereas Deposit Liabilities is likely to drop slightly above 165.5 K in 2022.
Last ReportedProjected for 2022
Book Value per Share 28.85  31.13 
Enterprise Value over EBIT 3.60  3.88 
Enterprise Value over EBITDA 3.77  3.87 
Price to Book Value 2.00  2.02 
Tangible Assets Book Value per Share 35.49  38.29 
Enterprise Value1.4 B1.5 B
Tangible Asset Value805.5 M869.1 M

Technical Drivers

As of the 21st of January, Fulgent Genetics shows the coefficient of variation of (2,179), and Mean Deviation of 3.24. Fulgent Genetics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Fulgent Genetics, which can be compared to its rivals. Please confirm Fulgent Genetics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Fulgent Genetics is priced favorably, providing market reflects its regular price of 61.5 per share. Given that Fulgent Genetics has jensen alpha of (0.21), we urge you to verify Fulgent Genetics's prevailing market performance to make sure the company can sustain itself at a future point.

Fulgent Genetics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Fulgent Genetics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Fulgent Genetics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulgent Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulgent Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fulgent Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Fulgent Genetics Predictive Daily Indicators

Fulgent Genetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fulgent Genetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Fulgent Genetics Forecast Models

Fulgent Genetics time-series forecasting models is one of many Fulgent Genetics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fulgent Genetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Fulgent Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Fulgent Genetics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fulgent shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Fulgent Genetics. By using and applying Fulgent Stock analysis, traders can create a robust methodology for identifying Fulgent entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin 0.79  0.85 
Gross Margin 0.91  0.79 
Profit Margin 0.58  0.63 
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. Fulgent Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 480 people.

Current Fulgent Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fulgent analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fulgent analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
141.0Strong Buy1Odds
Fulgent Genetics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Fulgent analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Fulgent stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Fulgent Genetics, talking to its executives and customers, or listening to Fulgent conference calls.
Fulgent Analyst Advice Details

Fulgent Stock Analysis Indicators

Fulgent Genetics stock analysis indicators help investors evaluate how Fulgent Genetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Fulgent Genetics shares will generate the highest return on investment. By understating and applying Fulgent Genetics stock analysis, traders can identify Fulgent Genetics position entry and exit signals to maximize returns.
Quick Ratio4.05
Fifty Two Week Low62.50
Revenue Growth124.00%
Shares Short Prior Month2.65M
Average Daily Volume Last 10 Day586.19k
Average Daily Volume In Three Month479.42k
Earnings Growth98.50%
Shares Percent Shares Out6.98%
Earnings Quarterly Growth162.70%
Gross Margins80.19%
Short Percent Of Float9.94%
Forward Price Earnings12.75
Float Shares18.73M
Fifty Two Week High189.89
Enterprise Value To Ebitda2.79
Fifty Day Average89.52
Two Hundred Day Average86.04
Enterprise Value To Revenue2.07
Please check Investing Opportunities. Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Fulgent Stock analysis

When running Fulgent Genetics price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Fulgent Genetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.